Abbott’s financial performance is on track, with the company well-positioned to deliver on its key commitments. The second-quarter results show steady growth across multiple business segments, contributing to a 7.5% increase in organic sales compared to the same period last year.
Worldwide sales totaled $11.1 billion, driven by strong demand for Medical Devices, which saw a 12% organic increase. Diabetes Care sales also grew significantly, with a 19% organic rise. Established Pharmaceuticals and Adult Nutrition segments performed well, with double-digit increases in several countries.
Adjusted diluted earnings per share (EPS) rose to $1.26, reflecting double-digit growth compared to the prior year. Abbott narrowed its full-year 2025 adjusted diluted EPS guidance range to $5.10-$5.20, indicating continued momentum.
The company is advancing its pipeline with purpose, delivering on its mission to broaden the impact of breakthrough technologies. Notable milestones include delivering results from clinical trials and advancing product development.
Please note that some statements in this news release may be forward-looking statements. Abbott cautions that these statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated.
Source: https://www.abbott.com/corpnewsroom/strategy-and-strength/abbotts-diversified-healthcare-leadership-fuels-q2-results.html